SAG
AUTL

SageView Advisory Group’s Autolus Therapeutics AUTL Stock Holding History

SageView Advisory Group’s Portfolio AUTL Stock Details AUTL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-75
Closed -$150 – 718
2025
Q4 		$150 Buy
+75
New +$115 ﹤0.01% 2522

Other funds holding AUTL

MCO
MAK Capital One New York $714M AUM 68.07% 1-Year Est. Return
Blackstone Inc
Blackstone Inc New York $32.9B AUM 23.66% 1-Year Est. Return
SP
Syncona Portfolio St Peter Port, Guernsey $26.6M AUM 10.36% 1-Year Est. Return
AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
TAM
TFG Asset Management Grand Cayman, Cayman Islands $635M AUM 28.07% 1-Year Est. Return
Schroder Investment Management Group
Schroder Investment Management Group London, United Kingdom $141B AUM 34.18% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
BNP Paribas Asset Management
BNP Paribas Asset Management Paris, France $99.8B AUM 45.22% 1-Year Est. Return
LCM
Laurion Capital Management New York $3.9B AUM 75.03% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

SageView Advisory Group's AUTL Position: Q1 2026 in Review

SageView Advisory Group sold out of Autolus Therapeutics (AUTL) in Q1 2026, closing a stake of 75 shares — an estimated $150 sold.

SageView Advisory Group first reported a position in AUTL in Q4 2025 and held it in 1 quarter. The position peaked at $150 in Q4 2025. 84 funds tracked by Wall St. Rank hold AUTL as of Q1 2026.

  • SageView Advisory Group reported no remaining Autolus Therapeutics position as of Q1 2026 after selling out during the quarter.
  • SageView Advisory Group sold 75 Autolus Therapeutics shares in Q1 2026, an estimated $150.
  • SageView Advisory Group first reported a position in Autolus Therapeutics in Q4 2025 and held it in 1 quarter.
  • SageView Advisory Group's Autolus Therapeutics position peaked at $150 in Q4 2025.
  • 84 funds tracked by Wall St. Rank held Autolus Therapeutics as of Q1 2026.

Based on SageView Advisory Group's 13F filing for Q1 2026, filed 10 Aug 2026.